Syros Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 3.24
Dividend & YieldN/A$ (N/A)
Beta 1.48
Market capitalization 77.47M
Operating cash flow -114.95M
ESG Scores unknown

Company description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio4.33
Working Capital-0.82
Return On Equity-1.02
Debt To Equity0.47
Fixed Asset Ratio-0.19
Fixed Interest Cover-25.45

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 11.09M 19.67M -7.35M -11.86M
Total Cashflows From Investing Activities -10.64M -11.73M 46.66M -52.65M
Net Borrowings -50k -205k 39.38M -265k
Total Cash From Financing Activities 69.08M 65.99M 142.95M 70.51M
Change To Operating Activities 3.3M 4.24M 1.61M 1.9M
Issuance Of Stock 69.13M 61.56M 103.78M 70.82M
Net Income -62.28M -75.44M -84.04M -86.56M
Change In Cash 18.13M -6M 132.25M -81.68M
Effect Of Exchange Rate
Total Cash From Operating Activities -40.31M -60.25M -57.36M -99.54M
Depreciation 1.6M 2.72M 3.04M 3.02M
Change To Account Receivables -20.16M -20.16M 17.83M -648k
Other Cashflows From Financing Activities -207k -207k -207k -41k
Change To Netincome 5.97M 8.71M 11.27M -6.1M
Capital Expenditures -1.38M -12.64M -3.34M -1.25M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 50.18M 58.24M 76.06M 99.87M
Income Before Tax -62.28M -75.44M -84.04M -86.56M
Net Income -62.28M -75.44M -84.04M -86.56M
Selling General Administrative 16.16M 21.48M 21.32M 23.04M
Gross Profit 2.05M 1.98M 15.09M 23.49M
Ebit -64.3M -77.74M -82.3M -99.42M
Operating Income -64.3M -77.74M -82.3M -99.42M
Interest Expense -1k -72k -1.79M -3.91M
Income Tax Expense
Total Revenue 2.05M 1.98M 15.09M 23.49M
Cost Of Revenue
Total Other Income ExpenseNet 2.02M 2.3M -1.74M 12.86M
Net Income From Continuing Ops -62.28M -75.44M -84.04M -86.56M
Net Income Applicable To Common Shares -62.28M -75.44M -84.04M -86.56M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 28.18M 70.79M 122.7M 97.72M
Total Stockholder Equity 78.59M 79.18M 90.55M 85.22M
Other Current Liabilities 2.32M 5.74M 12.21M 10.18M
Total Assets 106.77M 149.98M 213.25M 182.94M
Common Stock 34k 43k 56k 61k
Other Current Assets 638k 290k
Retained Earnings -217.54M -292.98M -377.02M -463.58M
Treasury Stock -3k 24k -79k
Cash 49.89M 41.44M 173.98M 92.3M
Total Current Liabilities 19.53M 23.52M 28.62M 31.51M
Other Stockholder Equity -3k 24k -79k
Property, Plant, and Equipment 3.86M 31.89M 29.64M 27.29M
Total Current Assets 101.73M 114.51M 178.56M 136.59M
Net Tangible Assets 78.59M 79.18M 90.55M 85.22M
Net Receivables 20.16M 2.33M 2.98M
Accounts Payable 3.31M 5.85M 3.6M 3.69M


Insider Transactions

Here are the insider transactions of stock shares related to Syros Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
OLSON ERIC R.Sale at price 3.47 per share.D2022-01-05Officer2.21k
OLSON ERIC R.Sale at price 5.55 per share.D2021-07-01Officer1.16k
OLSON ERIC R.Sale at price 9.47 per share.D2021-03-15Officer3.63k
OLSON ERIC R.Conversion of Exercise of derivative security at price 1.01 per share.D2021-03-15Officer3.63k
YOUNG RICHARD ASale at price 12.05 per share.D2021-02-16Director3.75k
YOUNG RICHARD ASale at price 13.04 per share.D2021-02-08Director3.75k
SIMONIAN NANCY AConversion of Exercise of derivative security at price 3.04 - 10.09 per share.D2020-12-18Chief Executive Officer29.92k
AKKARAJU SRINIVASI2020-12-08Director625k
YOUNG RICHARD ASale at price 8.75 - 8.98 per share.D2020-11-17Director5.99k
YOUNG RICHARD ASale at price 8.75 - 8.98 per share.D2020-11-17Director5.99k
YOUNG RICHARD ASale at price 8.75 per share.D2020-10-19Director5.67k
YOUNG RICHARD ASale at price 8.75 per share.D2020-10-15Director317
YOUNG RICHARD ASale at price 10.39 per share.D2020-09-15Director5.99k
AKKARAJU SRINIVASSale at price 13.00 - 13.10 per share.I2020-08-18Director159.33k
OLSON ERIC R.Sale at price 13.00 per share.D2020-08-18Officer15.75k
OLSON ERIC R.Conversion of Exercise of derivative security at price 1.01 per share.D2020-08-18Officer15.75k
YOUNG RICHARD ASale at price 12.59 per share.D2020-08-17Director5.99k
YOUNG RICHARD ASale at price 11.85 per share.D2020-07-15Director5.99k
OLSON ERIC R.Sale at price 11.72 per share.D2020-07-07Officer1.75k
AKKARAJU SRINIVASSale at price 11.01 per share.I2020-07-01Director4.63k
AKKARAJU SRINIVASSale at price 11.07 - 11.15 per share.I2020-06-25Director154.7k
YOUNG RICHARD ASale at price 8.75 per share.D2020-06-15Director5.99k
YOUNG RICHARD ASale at price 9.22 per share.D2020-05-15Director5.99k
ALLES MARK JPurchase at price 8.86 per share.D2020-05-13Director10k
YOUNG RICHARD ASale at price 8.75 per share.D2020-04-15Director23.96k
OLSON ERIC R.Sale at price 7.38 per share.D2020-02-18Officer1.45k
SIMONIAN NANCY AConversion of Exercise of derivative security at price 3.04 per share.D2019-12-23Chief Executive Officer52.4k
SPRINGHORN JEREMY PPurchase at price 4.97 - 4.99 per share.D2019-11-12Officer20k
YOUNG RICHARD ASale at price 10.00 per share.D2019-08-16Director25k
ARCH VENTURE FUND VII LPSale at price 7.70 - 8.27 per share.I2019-07-17Beneficial Owner of more than 10% of a Class of Security63k
AKKARAJU SRINIVASPurchase at price 7.50 per share.I2019-04-09Director533.33k
ARCH VENTURE FUND VII LPSale at price 7.37 - 8.20 per share.I2019-03-14Beneficial Owner of more than 10% of a Class of Security167.5k
ARCH VENTURE FUND VII LPSale at price 6.49 - 6.93 per share.I2019-03-11Beneficial Owner of more than 10% of a Class of Security164.58k
QUIRK GERALD E.D2019-02-12Officer87k
SIMONIAN NANCY AD2019-02-12Chief Executive Officer188k
ROTH DAVID A M.D.D2019-02-12Officer87k
OLSON ERIC R.D2019-02-12Officer87k
SPRINGHORN JEREMY PD2019-02-12Officer87k
FERRA JOSEPH J. JR.D2019-02-12Chief Financial Officer87k
SIMONIAN NANCY AConversion of Exercise of derivative security at price 1.01 - 3.04 per share.D2018-11-29Chief Executive Officer110.59k
AKKARAJU SRINIVASPurchase at price 9.55 per share.I2018-01-31Director209.42k
SPRINGHORN JEREMY PPurchase at price 9.08 per share.D2017-12-15Officer15k
AKKARAJU SRINIVASPurchase at price 8.97 - 9.40 per share.I2017-12-14Director109.77k
DESIMONE COLLEEN ELIZABETHSale at price 16.06 per share.D2017-10-23Officer550
DESIMONE COLLEEN ELIZABETHConversion of Exercise of derivative security at price 3.04 per share.D2017-10-23Officer550
AFEYAN NOUBAR BOGHOSD2017-09-08Beneficial Owner of more than 10% of a Class of Security24.53k
YOUNG RICHARD ASale at price 22.00 per share.D2017-08-14Director3.28k
OLSON ERIC R.Sale at price 23.59 per share.D2017-08-07Officer2.5k
OLSON ERIC R.Conversion of Exercise of derivative security at price 1.01 per share.D2017-08-07Officer2.5k
YOUNG RICHARD ASale at price 22.09 per share.D2017-07-25Director3.28k
OLSON ERIC R.Sale at price 21.85 per share.D2017-07-25Officer12.5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Syros Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Syros Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Syros Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Syros Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Syros Pharmaceuticals Inc:

Syros Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -39.26% on the backtest period.

Performance at glance

Performance

-39.26 %

Latent gain

-885.04 $

Invested capital

2254.03 $

Annualized return

-9.48 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Syros Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Syros Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Syros Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Syros Pharmaceuticals Inc:

Syros Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give -37.59% of return on Syros Pharmaceuticals Inc. That represents -2071.28$ of latent gain with 5510.44$ of employed capital.
  • The second momentum investment strategy would give -31.1% of return on Syros Pharmaceuticals Inc. That represents -1397.4$ of latent gain with 4493.13$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-37.59 %

Latent gain

-2071.28 $

Invested capital

5510.44 $

Annualized return

-16.49 %
Performance at glance (2Q Momentum)

Performance

-31.1 %

Latent gain

-1397.4 $

Invested capital

4493.13 $

Annualized return

-8.5 %

Momentum equity curve on Syros Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Syros Pharmaceuticals Inc:

Syros Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Syros Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Syros Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Syros Pharmaceuticals Inc since the beginning:

Syros Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Syros Pharmaceuticals Inc

Buy the dip entry openings on Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc

The performance achieved by the robo-advisor on Syros Pharmaceuticals Inc is -35.28%. That represents -439.44$ of latent gain with 1245.57$ of employed capital. The following chart shows Syros Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Syros Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-35.28 %

Latent gain

-439.44 $

Invested capital

1245.57 $

Annualized return

-16.49 %

Equity curve of the strategy applied to Syros Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Syros Pharmaceuticals Inc:

Syros Pharmaceuticals Inc

Note: the dividends potentially given by Syros Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Syros Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Syros Pharmaceuticals Inc:

Syros Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Syros Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Syros Pharmaceuticals Inc.

Equity curve comparison on Syros Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Syros Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc investment comparison

Performance comparison on Syros Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -39.26% -885.04$ 2254.03$ -9.48%
Momentum 1 quarter -37.59% -2071.28$ 5510.44$ -9.64%
Momentum 2 quarters -31.1% -1397.4$ 4493.13$ -8.5%
Non-directional -35.28% -439.44$ 1245.57$ -16.49%
Annualized return comparison

Automatic investment

-9.48 %

Momentum 1Q

-8.5 %

Momentum 2Q

-8.5 %

Non-directional

-16.49 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Syros Pharmaceuticals Inc:

Positive correlations

Most correlated stocks this year

  • Syros Pharmaceuticals Inc

  • Most correlated stocks last 3 months

  • WEDIA
  • Syros Pharmaceuticals Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • CHINA STATE CON
  • LIFEBRANDZ
  • ANGANG STEEL
  • COUNTRY GARDEN
  • CHI MER LAND

  • Note: The algorithm computes the probability of correlation between Syros Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Syros Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Syros Pharmaceuticals Inc
    Country United States
    City Cambridge
    Address 35 CambridgePark Drive
    Phone 617 744 1340
    Website www.syros.com
    FullTime employees 124
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker SYRS
    Market www.nasdaq.com

    Syros Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown